[go: up one dir, main page]

BRPI0508364A - derivados de 4-benzimidazol-2-ilpiridazin-3-ona - Google Patents

derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Info

Publication number
BRPI0508364A
BRPI0508364A BRPI0508364-8A BRPI0508364A BRPI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A BR PI0508364 A BRPI0508364 A BR PI0508364A
Authority
BR
Brazil
Prior art keywords
benzimidazol
compounds
derivatives
ylpyridazin
kinase inhibitors
Prior art date
Application number
BRPI0508364-8A
Other languages
English (en)
Inventor
Swen Hoelder
Karl Schoenafinger
David William Will
Hans Matter
Guenther Mueller
Cecile Combeau
Christine Delaisi
Anke Steinmetz
Ingrid Sassoon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0508364A publication Critical patent/BRPI0508364A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE 4-BENZIMIDAZOL-2-ILPIRIDAZIN-3-ONA. A presente invenção refere-se a compostos da fórmula geral (l), onde a definição dos substituintes A, B, D, E, R¬ 1¬ e R¬ 2¬ são detalhadas na descrição, e os seus sais fisioligicamente tolerados, a um processo para a preparação destes compostos e a seu uso como produtos farmacêuticos. Estes compostos são inibidores de quinase, em particular inibidores da quinase CDK2 (quinase 2 dependente de ciclina).
BRPI0508364-8A 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona BRPI0508364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004010207A DE102004010207A1 (de) 2004-03-02 2004-03-02 Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
PCT/EP2005/002569 WO2005085231A1 (en) 2004-03-02 2005-02-18 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives

Publications (1)

Publication Number Publication Date
BRPI0508364A true BRPI0508364A (pt) 2007-07-24

Family

ID=34853913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508364-8A BRPI0508364A (pt) 2004-03-02 2005-02-18 derivados de 4-benzimidazol-2-ilpiridazin-3-ona

Country Status (14)

Country Link
US (2) US7470689B2 (pt)
EP (1) EP1723137A1 (pt)
JP (1) JP4792455B2 (pt)
KR (1) KR20070008582A (pt)
CN (1) CN101061108A (pt)
AR (1) AR047987A1 (pt)
AU (1) AU2005219563A1 (pt)
BR (1) BRPI0508364A (pt)
CA (1) CA2555161A1 (pt)
DE (1) DE102004010207A1 (pt)
IL (1) IL177204A0 (pt)
TW (1) TW200538452A (pt)
UY (1) UY28783A1 (pt)
WO (1) WO2005085231A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP2298770A1 (en) * 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
MY148634A (en) * 2006-07-25 2013-05-15 Cephalon Inc Pyridazinone derivatives
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324580A1 (de) 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
CA2294548A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
ATE258928T1 (de) * 1999-06-28 2004-02-15 Janssen Pharmaceutica Nv Respiratorisches syncytialvirus replikation inhibitoren
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
EE200300475A (et) * 2001-03-28 2004-02-16 Bristol-Myers Squibb Company Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
PL366889A1 (en) 2001-07-27 2005-02-07 Yamanouchi Pharmaceutical Co, Ltd. Novel crystal of arylethenesulfonamide derivative and process for producing the same
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005519895A (ja) 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
EP2322521B1 (en) 2002-02-06 2013-09-04 Vertex Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of GSK-3
BR0308109A (pt) 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
HU227255B1 (en) * 2002-04-26 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
US7232906B2 (en) 2002-06-05 2007-06-19 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
KR20050084271A (ko) 2002-12-12 2005-08-26 아방티 파르마 소시에테 아노님 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도
IL157751A0 (en) 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
EP1604984A1 (en) * 2003-03-18 2005-12-14 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US7232939B2 (en) 2004-05-28 2007-06-19 E.I. Du Pont De Nemours And Company Nucleic acid molecules encoding cyclotide polypeptides and methods of use
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
US7754713B2 (en) 2010-07-13
UY28783A1 (es) 2005-09-30
CA2555161A1 (en) 2005-09-15
EP1723137A1 (en) 2006-11-22
AU2005219563A1 (en) 2005-09-15
JP2007531712A (ja) 2007-11-08
WO2005085231A1 (en) 2005-09-15
DE102004010207A1 (de) 2005-09-15
IL177204A0 (en) 2006-12-10
AR047987A1 (es) 2006-03-15
US20070173503A1 (en) 2007-07-26
CN101061108A (zh) 2007-10-24
US20090042880A1 (en) 2009-02-12
KR20070008582A (ko) 2007-01-17
US7470689B2 (en) 2008-12-30
TW200538452A (en) 2005-12-01
JP4792455B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
BRPI0508364A (pt) derivados de 4-benzimidazol-2-ilpiridazin-3-ona
BRPI0510410A (pt) compostos orgánicos
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0519674A2 (pt) sulfonil pirrolidinas, mÉtodo para produzir as mesmas e seu uso como drogas
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0512797A (pt) derivados de quinazolinona como inibidores de parp
BRPI0510412A (pt) compostos orgánicos
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0607577A2 (pt) antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0512060B8 (pt) compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR9909688A (pt) Indolinonas substituìdas, a sua preparação e seu uso como composições farmacêuticas
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0514091A (pt) 8-aminoalquiltioxantinas substituìdas, e seu uso como inibidores de dipepetidil peptidase iv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.